Triptorelin Extended-Release Suspension (Triptodur®)

Triptodur (triptorelin ER) is covered for pediatric central precocious puberty in patients ≥2 years and for compendial off‑label use in gender‑dysphoric/gender‑incongruent individuals or those undergoing gender reassignment; all other uses are not authorized. Authorization requires diagnosis and age documentation (for CPP), adherence to the 22.5 mg IM every 24 weeks dosing, prescriber or endocrinologist/transgender‑specialist consultation for transgender-related uses, meeting applicable safety criteria, and is granted for up to 12 months.

"Treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP)."

Sign up to see full coverage criteria, indications, and limitations.